Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04400695). This is a study registration, not published results. Lead sponsor: RemeGen Co., Ltd.. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 366 participants (ESTIMATED). Conditions: Breast Cancer. Interventions: DRUG: RC48-ADC; DRUG: Paclitaxel Injection; DRUG: Docetaxel Injection; DRUG: Vinorelbine Tartrate Injection; DRUG: Capecitabine Tablets. Primary outcome measures: Progression-free survival (PFS), evaluated by an independent efficacy evaluation committee , within approximately 3 years. Brief summary: This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ，previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.